BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12419751)

  • 1. A phase III randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil and mitomycin C versus 5-fluorouracil alone in curatively resected gastric cancer.
    Chang HM; Jung KH; Kim TY; Kim WS; Yang HK; Lee KU; Choe KJ; Heo DS; Bang YJ; Kim NK
    Ann Oncol; 2002 Nov; 13(11):1779-85. PubMed ID: 12419751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma.
    Koo DH; Lee JL; Kim TW; Chang HM; Ryu MH; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
    Eur J Surg Oncol; 2007 Sep; 33(7):843-8. PubMed ID: 17207959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
    Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
    Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study.
    Macdonald JS; Fleming TR; Peterson RF; Berenberg JL; McClure S; Chapman RA; Eyre HJ; Solanki D; Cruz AB; Gagliano R
    Ann Surg Oncol; 1995 Nov; 2(6):488-94. PubMed ID: 8591078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
    Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
    Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
    Park JO; Chung HC; Cho JY; Rha SY; You NC; Kim JH; Noh SH; Kim CB; Min JS; Kim BS; Roh JK
    Am J Clin Oncol; 1997 Oct; 20(5):484-9. PubMed ID: 9345333
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose 5-fluorouracil / folinic acid in combination with three-weekly mitomycin C in the treatment of advanced gastric cancer. A phase II study.
    Hofheinz RD; Hartung G; Samel S; Hochhaus A; Pichlmeier U; Post S; Hehlmann R; Queisser W
    Onkologie; 2002 Jun; 25(3):255-60. PubMed ID: 12119460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer.
    Lise M; Nitti D; Marchet A; Sahmoud T; Buyse M; Duez N; Fiorentino M; Dos Santos JG; Labianca R; Rougier P
    J Clin Oncol; 1995 Nov; 13(11):2757-63. PubMed ID: 7595735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion.
    Choi JH; Kim YB; Lim HY; Park JS; Kim HC; Cho YK; Han SW; Kim MW; Joo HJ
    Hepatogastroenterology; 2007; 54(73):290-7. PubMed ID: 17419278
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prospective randomized trial comparing modified FAM (5-fluorouracil (5-FU) + adriamycin + mitomycin C) versus 5-FU alone for the treatment of non-resectable pancreatic and biliary tract carcinomas (the 1st trial in non-resectable patients). Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract].
    Takada T; Kato H; Sasaki M; Matsushiro T; Yamauchi H; Kajihara T; Watanabe G; Hanaue H; Yoshida K; Shimizu T
    Gan To Kagaku Ryoho; 1992 Aug; 19(9):1295-301. PubMed ID: 1503483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer.
    Chen S; Chen YB; Zhou ZW; Li W; Sun XW; Xu DZ; Li YF; Guan YX; Feng XY; Zhan YQ
    Am J Clin Oncol; 2011 Jun; 34(3):309-13. PubMed ID: 20838324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gastric carcinoma: curative resection and adjuvant chemotherapy.
    Carrillo Hernández JF; Ernesto de Obaldía Castillo G; Ramírez Ortega C; Frías Mendivil M; Pardo M
    Arch Med Res; 1994; 25(1):29-35. PubMed ID: 8019111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant 5-fluorouracil plus doxorubicin in D2-3 resected gastric carcinoma: 15-year experience at a single institute.
    Jeung HC; Rha SY; Noh SH; Min JS; Kim BS; Chung HC
    Cancer; 2001 Jun; 91(11):2016-25. PubMed ID: 11391580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II study.
    Hartmann JT; Pintoffl JP; Al-Batran SE; Quietzsch D; Meisinger I; Horger M; Nehls O; Bokemeyer C; Königsrainer A; Jäger E; Kanz L
    Onkologie; 2007 May; 30(5):235-40. PubMed ID: 17460417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line treatment with a combination of continuous 5-fluorouracil, doxorubicin, and mitomycin-C (conti-FAM) in gemcitabine-pretreated pancreatic and biliary tract cancer.
    Lee S; Oh SY; Kim BG; Kwon HC; Kim SH; Rho MH; Kim YH; Rho MS; Jeong JS; Kim HJ
    Am J Clin Oncol; 2009 Aug; 32(4):348-52. PubMed ID: 19363436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection.
    Choi JH; Lim HY; Joo HJ; Kim HS; Yi JW; Kim HC; Cho YK; Kim MW; Lee KB
    Br J Cancer; 2002 May; 86(10):1578-85. PubMed ID: 12085207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficiency of adjuvant immunochemotherapy following curative resection in patients with locally advanced gastric cancer.
    Popiela T; Kulig J; Czupryna A; Szczepanik AM; Zembala M
    Gastric Cancer; 2004; 7(4):240-5. PubMed ID: 15616772
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
    Jeung HC; Moon YW; Rha SY; Yoo NC; Roh JK; Noh SH; Min JS; Kim BS; Chung HC
    Ann Oncol; 2008 Mar; 19(3):520-6. PubMed ID: 18029971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of irinotecan and mitomycin C in 5-fluorouracil-pretreated patients with advanced colorectal and gastric cancer.
    Bamias A; Papamichael D; Syrigos K; Pavlidis N
    J Chemother; 2003 Jun; 15(3):275-81. PubMed ID: 12868555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical Oncology Group 9206-1.
    Nashimoto A; Nakajima T; Furukawa H; Kitamura M; Kinoshita T; Yamamura Y; Sasako M; Kunii Y; Motohashi H; Yamamoto S;
    J Clin Oncol; 2003 Jun; 21(12):2282-7. PubMed ID: 12805327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.